The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Subscribe To Our Newsletter & Stay Updated
